Business ❯Stock Market ❯Market Reactions
AbbVie Stock Market Performance Trading Activity Trade Tariffs U.S. Dollar Treasury Yields
AbbVie's emraclidine failed to meet key endpoints in Phase 2 trials, impacting its $8.7 billion acquisition of Cerevel Therapeutics.
